ScinoPharm Taiwan, Ltd. (TPE:1789)
Taiwan
· Delayed Price · Currency is TWD 20.60
-1.05 (-4.85%)
Mar 9, 2026, 1:30 PM CST
ScinoPharm Taiwan Revenue
In the year 2025, ScinoPharm Taiwan had annual revenue of 3.16B TWD, down -7.13%. ScinoPharm Taiwan had revenue of 1.01B in the quarter ending December 31, 2025, a decrease of -2.74%.
Revenue
3.16B
Revenue Growth
-7.13%
P/S Ratio
5.15
Revenue / Employee
5.86M
Employees
540
Market Cap
16.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.16B | -242.86M | -7.13% |
| Dec 31, 2024 | 3.41B | 220.20M | 6.91% |
| Dec 31, 2023 | 3.19B | -77.96M | -2.39% |
| Dec 31, 2022 | 3.26B | 501.71M | 18.16% |
| Dec 31, 2021 | 2.76B | -320.59M | -10.40% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grape King Bio | 10.25B |
| Synmosa Biopharma | 6.11B |
| YungShin Global Holding | 8.37B |
| TTY Biopharm Company | 6.50B |
| Foresee Pharmaceuticals | 519.61M |
| Alar Pharmaceuticals | 1.25M |
| Handa Pharmaceuticals | 1.62B |
| Standard Chemical & Pharmaceutical | 7.02B |
ScinoPharm Taiwan News
- 2 months ago - ScinoPharm Wins First FDA Approval With Glatiramer Acetate Injection For Multiple Sclerosis - Nasdaq